Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

Authors
Han, ChangsuWang, Sheng-MinBahk, Won-MyongLee, Soo-JungPatkar, Ashwin A.Masand, Prakash S.Mandelli, LauraPae, Chi-UnSerretti, Alessandro
Issue Date
11월-2018
Publisher
KOREAN COLL NEUROPSYCHOPHARMACOLOGY
Keywords
Depressive disorder; Pharmacogenetic testing; Antidepressants; Precision medicine; Effects; Tolerance
Citation
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.16, no.4, pp.469 - +
Indexed
SCIE
SCOPUS
KCI
Journal Title
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
Volume
16
Number
4
Start Page
469
End Page
+
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/72029
DOI
10.9758/cpn.2018.16.4.469
ISSN
1738-1088
Abstract
Objective: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. Methods: An 8-week, randomized, single-blind clinical trial was conducted to evaluate the effectiveness and tolerability of PGATx in 100 patients with MDD. All recruited patients were randomly allocated either to PGATx (n=52) or treatment as usual (TAU, n=48) groups. The primary endpoint was a change of total score of the Hamilton Depression Rating Scale-17 (HAMD-17) from baseline to end of treatment. Response rate (at least 50% reduction in HAMD-17 score from baseline), remission rate (HAMD-17 score <= 7 at the end of treatment) as well as the change of total score of Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) from baseline to end of treatment were also investi gated. Results: The mean change of HAMD-17 score was significantly different between two groups favoring PGATx by -4.1 point of difference (p=0.010) at the end of treatment. The mean change in the FIBSER score from baseline was significantly different between two treatment groups favoring PGATx by -2.5 point of difference (p=0.028). The response rate (71.7 % vs. 43.6%, p=0.014) were also significantly higher in PGATx than in TAU at the end of treatment, while the remission rate was numerically higher in PGATx than in TAU groups without statistical difference (45.5% vs. 25.6%, p=0.071). The reason for early drop-out associated with adverse events was also numerically higher in TAU (n=9, 50.0%) than in PGATx (n=4, 30.8%). Conclusion: The present study clearly demonstrate that PGATx may be a better treatment option in the treatment of MDD in terms of effectiveness and tolerability; however, study shortcomings may limit a generalization. Adequately-powered, well-designed, subsequent studies should be mandatory to prove its practicability and clinical utility for routine practice.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Han, Chang su photo

Han, Chang su
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE